Is Kesimpta better than Ocrevus?

Drugs.com

Official answer

by Drugs.com

  • In patients with relapsing forms of multiple sclerosis, Kesimpta is thought to be more effective than Ocrevus in some ways, but no clinical trials have directly compared the two drugs

  • Ocrevus is the only one of the two drugs approved to treat primary progressive multiple sclerosis

    • Kesimpta (ofatumumab) and Ocrevus (ocrelizumab) are prescription medications used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Ocrevus is also used to treat primary progressive MS in adults.

    Kesimpta and Ocrevus have not been compared head-to-head in a clinical trial in patients with relapsing forms of MS, but an indirect comparison indicates that Kesimpta is better than Ocrevus when looking at certain measures of effectiveness.

    Researchers have compared the data from two Kesimpta trials (ASCLEPIOS I and ASCLEPIOS II) with data from two Ocruvus trials (OPERA I AND OPERA II) using simulated treatment comparisons.

    The researchers found that for the patients with three- and six-month confirmed disability progression, the two drugs appear to be similarly effective. However, treatment with Kesimpta appears to provide a significant improvement in annualized relapse rates (rate ratio: 0.60, 95% CI: 0.43-0.84) compared with Ocrevus, meaning that patients treated with Kesimpta were less likely to experience relapses. Magnetic resonance imaging (MRI) outcomes, which looked at the proportion of patients with gadolinium-enhancing T1 lesions and brain volume change, and NEDA-3 (No Evidence of Disease Activity 3 parameter composite measure) outcomes also significantly favored Kesimpta over Ocrevus.

    Kesimpta and Ocrevus are both CD20-directed cytolytic monoclonal antibodies that target B-cells. Exactly how these drugs work is unknown, but it’s thought to be related to their ability to deplete B cells, which reduces the number of relapses patients with MS experience and slows the progression of the disease.

    Kesimpta Ocrevus
    Company Novartis Pharmaceuticals Genentech
    Approved by the FDA 2009 2017
    Active ingredient Ofatumumab Ocrelizumab
    Uses Used to treat:
  • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
    		•  Used to treat:
  • Relapsing forms of MS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
  • Primary progressive MS, in adults.
    		•
    Drug class CD20 monoclonal antibody CD20 monoclonal antibody
    Route of administration Subcutaneous (under the skin) injections - Given weekly for three weeks then monthly Intravenous (infusion) injection - Given twice two weeks apart then six-monthly

    Related medical questions

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords